

LCP2 Antibody (N-term) Blocking Peptide

Synthetic peptide Catalog # BP8655a

Specification

LCP2 Antibody (N-term) Blocking Peptide - Product Information

Primary Accession

Q13094

LCP2 Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 3937

Other Names

Lymphocyte cytosolic protein 2, SH2 domain-containing leukocyte protein of 76 kDa, SLP-76 tyrosine phosphoprotein, SLP76, LCP2

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP8655a was selected from the N-term region of human LCP2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LCP2 Antibody (N-term) Blocking Peptide - Protein Information

Name LCP2

Function

Involved in T-cell antigen receptor mediated signaling.

Cellular Location

Cytoplasm.

Tissue Location

Highly expressed in spleen, thymus and peripheral blood leukocytes. Highly expressed also in T-cell and monocytic cell lines, expressed at lower level in B-cell lines. Not detected in fibroblast or neuroblastoma cell lines



LCP2 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

LCP2 Antibody (N-term) Blocking Peptide - Images

LCP2 Antibody (N-term) Blocking Peptide - Background

LCP2 is involved in T-cell antigen receptor mediated signaling.

LCP2 Antibody (N-term) Blocking Peptide - References

Motto, D.G., et.al., J. Exp. Med. 183 (4), 1937-1943 (1996) Bubeck Wardenburg, J., et.al., J. Biol. Chem. 271 (33), 19641-19644 (1996)